Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHN WILEY & SONS, INC.

(JW.A)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

John Wiley & Sons : Erythropoietin Treatments May Increase Hip Fracture Risk in Patients With Kidney Failure

05/05/2021 | 01:09am EDT

Erythropoietin (EPO) is a medication used to stimulate the production of new red blood cells, which is impaired in individuals with kidney failure. Unfortunately, however, the treatment may increase the risk of hip fractures.

In an analysis published in the Journal of Bone and Mineral Research that examined 1997-2013 records from two large U.S. databases, investigators found that EPO doses administered to patients with kidney failure on hemodialysis fluctuated widely over time, and hip fracture rates closely tracked the average dose of EPO doses used in patients.

'Patients with renal failure can benefit from EPO treatment; however, as with all medications, a full understanding of potential drug-associated risks favors the likelihood that a positive risk-benefit balance can be achieved with EPO treatment,' senior author Constance Tom Noguchi, PhD, of the National Institute of Diabetes and Digestive and Kidney Diseases.

Additional Information

Link to Study: https://onlinelibrary.wiley.com/doi/10.1002/jbmr.4297

About Journal

The Journal of Bone and Mineral Research (JBMR) publishes highly impactful original manuscripts, reviews, and special articles on basic, translational and clinical investigations relevant to the musculoskeletal system and mineral metabolism. Specifically, the journal is interested in original research on the biology and physiology of skeletal tissues, interdisciplinary research spanning the musculoskeletal and other systems, including but not limited to immunology, hematology, energy metabolism, cancer biology, and neurology, and systems biology topics using large scale '-omics' approaches. The journal welcomes clinical research on the pathophysiology, treatment and prevention of osteoporosis and fractures, as well as sarcopenia, disorders of bone and mineral metabolism, and rare or genetically determined bone diseases.

About Wiley

Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at www.wiley.com.

Disclaimer

John Wiley & Sons Inc. published this content on 05 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 May 2021 05:08:02 UTC.


ę Publicnow 2021
All news about JOHN WILEY & SONS, INC.
05/05JOHN WILEY & SONSá : New Study Identifies Quality Measures for End-of-Life Care ..
PU
05/05JOHN WILEY & SONSá : Many Patients With Cancer Are Experiencing Loneliness and R..
PU
05/05JOHN WILEY & SONSá : Which Medications Are Most Toxic to the Liver?
PU
05/05JOHN WILEY & SONSá : Do Bacteria in the Mouth Affect Risk of Developing Rheumato..
PU
05/05JOHN WILEY & SONSá : Erythropoietin Treatments May Increase Hip Fracture Risk in..
PU
05/05JOHN WILEY & SONSá : How Accurate Are Virtual Assessments of Cognitive Function?
PU
05/05JOHN WILEY & SONSá : The Online Learning Needs of Students Across Different Grad..
PU
05/05JOHN WILEY & SONSá : English as a Medium of Instruction in Higher Education Acro..
PU
05/05JOHN WILEY & SONSá : Light Pollution at Night Affects the Calls of Migratory Bir..
PU
05/05JOHN WILEY & SONSá : New Tool Offers Personalized, Low Environmental Impact, Hea..
PU
More news
Financials (USD)
Sales 2021 1 904 M - -
Net income 2021 139 M - -
Net Debt 2021 938 M - -
P/E ratio 2021 24,9x
Yield 2021 2,22%
Capitalization 3 435 M 3 435 M -
EV / Sales 2021 2,30x
EV / Sales 2022 2,19x
Nbr of Employees 6 900
Free-Float 52,3%
Chart JOHN WILEY & SONS, INC.
Duration : Period :
John Wiley & Sons, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHN WILEY & SONS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 55,33 $
Last Close Price 61,72 $
Spread / Highest target 0,45%
Spread / Average Target -10,3%
Spread / Lowest Target -22,2%
EPS Revisions
Managers and Directors
NameTitle
Brian A. Napack President, Chief Executive Officer & Director
John Anthony Kritzmacher Chief Financial Officer & Executive VP-Operations
Jesse C. Wiley Non-Executive Chairman
Aref Matin Chief Technology Officer & Executive VP
Raymond W. McDaniel Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHN WILEY & SONS, INC.34.17%3 414
S&P GLOBAL INC.15.51%91 465
RELX PLC1.79%49 331
THOMSON REUTERS CORPORATION9.91%46 733
MSCI INC.3.26%38 004
EQUIFAX INC.20.94%28 846